Measuring food noise on GLP-1s: what questionnaire scores tell you

Hunger, food thoughts and weight are different measurements

When someone says a GLP-1 medicine “changed my appetite,” several experiences might be involved: feeling hungry less often, feeling full sooner, having fewer cravings or spending less time distracted by food thoughts. Before interpreting a number, identify which experience the researchers actually asked about.

The 2023 food-cue conceptual model discusses several ways of studying responses to food, including self-reports and laboratory measures. A questionnaire about thoughts and a test involving food cues answer different questions. Neither should silently be substituted for the other in a treatment headline.

The same distinction applies to your own follow-up. A weight record and a description of intrusive thoughts can both be useful, but one does not stand in for the other. You can tell a clinician which part of your experience has changed and which part remains difficult.

One example: the five-item Food Noise Questionnaire

The Food Noise Questionnaire development study, published in 2025, analyzed complete responses from 396 participants. The FNQ contains five items about disruptive food-related thoughts. Responses are added to a total from 0 to 20, with higher totals indicating more food noise. Its original instructions ask about the preceding two weeks.

The researchers examined consistency between items, repeat responses and relationships with other questionnaires. Those are checks on the measurement tool. They are different from testing whether a particular medicine works. The authors called for more research on clinical usefulness; the paper also discloses several authors’ employment or shareholding ties to WW International.

Pennington Biomedical Research Center maintains an official FNQ resource and translations page. If your clinician uses a questionnaire, ask for the intended version and instructions. Changing wording or the recall period makes a result harder to compare with the published instrument.

What a recent semaglutide survey can show

The INFORM report, published in May 2026, surveyed 550 US adults currently using injectable semaglutide for weight management. Participants rated their current food noise and recalled how it had felt before treatment. Among 547 with complete FNQ data, the reported median individual change was a five-point reduction.

That finding records a perceived improvement in the surveyed group. There was no untreated comparison group, and the earlier ratings were reconstructed from memory. People who had already stopped semaglutide were not represented. The study was funded by Novo Nordisk and acknowledged recall and selection bias.

The report therefore supports further investigation; it cannot isolate how much change was caused by the medicine or predict an individual response. The authors also noted that the smallest FNQ change that constitutes a clinically meaningful benefit remained to be defined.

Four details to check behind an appetite claim

Keep the claim attached to its measurement. A statement about questionnaire responses should tell you which questionnaire was used. A statement about weight should identify the weight outcome. If an advertisement combines them into one success figure, look for the original results before drawing a conclusion.

• Question: did the study ask about intrusive thoughts, hunger, cravings, control of eating or something else?
• Timing: were answers collected before treatment, or did people later try to remember how they had felt?
• Comparison: was there another study group, and how were participants assigned to it?
• Population and product: who was studied, which medicine was used, and who was left out?

A diary supplies context that a total cannot

Imagine two people describing fewer distracting thoughts. One says planning lunch has become easier; the other says thoughts still disrupt evening family time. “Less than before” leaves those different needs hidden. These are fictional illustrations, not reported medication outcomes.

Our food-thought diary guide helps you describe the situations that matter without building your own rating system. A few observations can explain what you want help with. If tracking increases anxiety or preoccupation, stop the exercise and ask for another way to communicate.

For prescription weight management, the NIDDK overview emphasizes health history, expected benefits, side effects and other medicines in treatment selection. A food-noise score is not a substitute for that assessment, and an improvement in one experience does not settle every question about continuing care.

Take the observation into a CoreAge Rx care discussion

CoreAge Rx’s intake instructions ask for health history, medications and allergies for provider review. If you are considering the service, describe how food thoughts affect your day and ask whether additional assessment or support would be useful. A questionnaire completed online is not proof that a specific prescription is right for you.

Our CoreAge Rx review covers the service, and the official site describes its compounded semaglutide and tirzepatide offerings. Ask the clinician about the exact product and how benefit and tolerability would be reviewed. Research on another study population cannot establish food-noise outcomes for CoreAge Rx patients.

The FDA’s guidance explains that compounded GLP-1 drugs are not FDA-approved and should be used only when an approved drug cannot meet a patient’s medical needs. Evaluating the product remains a separate part of the conversation, even when an appetite-related concern feels familiar.

Common questions

Keep researching

• Describe food thoughts in a brief diary
• Investigate the CoreAge Rx service
• Browse Food Noise Stop articles